These findings possibly suggest that NGR1 pretreatment promotes hiPSC-CM survival post-transplantation and improves the therapeutic efficacy of hiPSC-CM transplantation in MI via PI3K/Akt pathway activation. The gene discussed is RTN4R; the disease is myocardial infarction.